Equivalent Weight Loss with Marked Metabolic Benefit Observed in a Matched Cohort with and Without Type 2 Diabetes 12 Months Following Gastric Bypass Surgery
Obesity Surgery, 08/20/2012
Yip K et al. – When matched on appropriate factors associated with weight loss outcomes, severely obese patients with T2DM have similar post–LRYGB weight loss outcomes in the first 12 months following surgery compared with non–T2DM patients. Furthermore, T2DM surgical patients achieved significant improvement in metabolic syndrome components.Methods
- Retrospective cohort analysis of T2DM patients (n=126) to non–T2DM patients (n=126) matched on age (M=48.1±9.5), sex (81 % female), race (81 % Caucasian), and pre–surgical BMI (M=49.3±9.5).
- Lipids, glucose, hemoglobin A1c, blood pressure, co–morbidities of obesity, medications for co–morbidities, and T2DM medications were collected at baseline, 6 months and 12 months post–surgery.
- %EBMIL was collected at 1, 3, 6, 9, and 12 months post–surgery.
- One–way analyses of variance with effect sizes estimates were conducted to compare the two groups.
- As expected, T2DM subjects had significantly greater pre–surgical HbA1c, blood glucose, blood pressure, and lipid parameters at baseline vs. non–T2DM (all p values of<0.05).
- At 1, 3, 6, 9, and 12 months after LRYRB, both groups had similar reduction in %EBMIL (p>0.10).
- At 6 months, there was a significant reduction in HbA1c, blood glucose, and lipid in the T2DM cohort compared with pre–surgical levels (p<0.0001).
- At 12 months, these values were not different to that of the non–T2DM subjects (p>0.10).